{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:49:32Z","timestamp":1785242972007,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,15]]},"DOI":"10.7759\/cureus.90196","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T05:13:24Z","timestamp":1755321204000},"source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of Insulin Versus Oral Agents in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Retrospective Comparative Study"],"prefix":"10.7759","author":[{"given":"Muhammad Hamza","family":"Naeem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudassir","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moaz Bin","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najeeb","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoya Azhar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinza","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66468-1","article-title":"Oral antidiabetic therapy versus early insulinization on glycemic control in newly diagnosed type 2 diabetes patients: a retrospective matched cohort study","volume":"14","author":"Lee YM","year":"2024","unstructured":"Lee YM, Lin PR, Sia HK. Oral antidiabetic therapy versus early insulinization on glycemic control in newly diagnosed type 2 diabetes patients: a retrospective matched cohort study. Sci Rep. 2024, 14:15491. 10.1038\/s41598-024-66468-1","journal-title":"Sci Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2004.04.013","article-title":"Pathogenesis of type 2 diabetes mellitus","volume":"88","author":"DeFronzo RA","year":"2004","unstructured":"DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004, 88:787-835, ix. 10.1016\/j.mcna.2004.04.013","journal-title":"Med Clin North Am"},{"key":"ref3","article-title":"Insulin versus an oral antidiabetic agent as add-on therapy in type 2 diabetes after failure of an oral antidiabetic regimen: a meta-analysis","volume":"2","author":"Gamble J","year":"2008","unstructured":"Gamble J, Simpson SH, Brown LC, Johnson JA. Insulin versus an oral antidiabetic agent as add-on therapy in type 2 diabetes after failure of an oral antidiabetic regimen: a meta-analysis. Open Med. 2008, 2:e26-38.","journal-title":"Open Med"},{"key":"ref4","article-title":"Oral and Injectable (Non-insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes","author":"Feingold KR","year":"2000","unstructured":"Feingold KR. Oral and Injectable (Non-insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes. Feingold KR, Ahmed SF, Anawalt B, et al. (ed): Endotext [Internet], South Dartmouth, MA; 2000."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0828-y","article-title":"Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives","volume":"18","author":"Cefalo CM","year":"2019","unstructured":"Cefalo CM, Cinti F, Moffa S, et al.. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol. 2019, 18:20. 10.1186\/s12933-019-0828-y","journal-title":"Cardiovasc Diabetol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2016.1168808","article-title":"Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus","volume":"20","author":"Song P","year":"2016","unstructured":"Song P, Onishi A, Koepsell H, Vallon V. Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Expert Opin Ther Targets. 2016, 20:1109-25. 10.1517\/14728222.2016.1168808","journal-title":"Expert Opin Ther Targets"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/2042018819890527","article-title":"A review of sotagliflozin for use in type 1 diabetes","volume":"10","author":"Nuffer W","year":"2019","unstructured":"Nuffer W, Williams B, Trujillo JM. A review of sotagliflozin for use in type 1 diabetes. Ther Adv Endocrinol Metab. 2019, 10:2042018819890527. 10.1177\/2042018819890527","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0311435","article-title":"Comparing dual oral agents plus insulin vs. triple oral agents in uncontrolled type II diabetes: a pilot study","volume":"19","author":"Gul N","year":"2024","unstructured":"Gul N, Rehman IU, Shah Y, et al.. Comparing dual oral agents plus insulin vs. triple oral agents in uncontrolled type II diabetes: a pilot study. PLoS One. 2024, 19:e0311435. 10.1371\/journal.pone.0311435","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg SK","year":"2017","unstructured":"Garg SK, Henry RR, Banks P, et al.. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017, 377:2337-48. 10.1056\/NEJMoa1708337","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0890","article-title":"Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy","volume":"38","author":"Rosenstock J","year":"2015","unstructured":"Rosenstock J, Cefalu WT, Lapuerta P, Zambrowicz B, Ogbaa I, Banks P, Sands A. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. Diabetes Care. 2015, 38:431-8. 10.2337\/dc14-0890","journal-title":"Diabetes Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.10.026","article-title":"LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion","volume":"37","author":"Zambrowicz B","year":"2015","unstructured":"Zambrowicz B, Lapuerta P, Strumph P, et al.. LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion. Clin Ther. 2015, 37:71-82.e12. 10.1016\/j.clinthera.2014.10.026","journal-title":"Clin Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2166","article-title":"Metabolic, intestinal, and cardiovascular effects of sotagliflozin compared with empagliflozin in patients with type 2 diabetes: a randomized, double-blind study","volume":"45","author":"Posch MG","year":"2022","unstructured":"Posch MG, Walther N, Ferrannini E, Powell DR, Banks P, Wason S, Dahmen R. Metabolic, intestinal, and cardiovascular effects of sotagliflozin compared with empagliflozin in patients with type 2 diabetes: a randomized, double-blind study. Diabetes Care. 2022, 45:2118-26. 10.2337\/dc21-2166","journal-title":"Diabetes Care"},{"key":"ref13","article-title":"Section 6: glycemic goals and hypoglycemia","volume":"43","year":"2025","unstructured":"Section 6. glycemic goals and hypoglycemia. Clin Diabetes. 2025, 43:198-203.","journal-title":"Clin Diabetes"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7326\/M21-0651","article-title":"Effect of sotagliflozin on total hospitalizations in patients with type 2 diabetes and worsening heart failure: a randomized trial","volume":"174","author":"Szarek M","year":"2021","unstructured":"Szarek M, Bhatt DL, Steg PG, et al.. Effect of sotagliflozin on total hospitalizations in patients with type 2 diabetes and worsening heart failure: a randomized trial. Ann Intern Med. 2021, 174:1065-72. 10.7326\/M21-0651","journal-title":"Ann Intern Med"},{"key":"ref15","article-title":"Insulin- Pharmacology, Therapeutic Regimens and Principles of Intensive Insulin Therapy","author":"Donnor T","year":"2000","unstructured":"Donnor T, Sarkar S. Insulin- Pharmacology, Therapeutic Regimens and Principles of Intensive Insulin Therapy. Feingold KR, Ahmed SF, Anawalt B, et al. (ed): Endotext [Internet], South Dartmouth, MA; 2000."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-018-1271-3","article-title":"Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus","volume":"56","author":"Sesti G","year":"2019","unstructured":"Sesti G, Avogaro A, Belcastro S, et al.. Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetol. 2019, 56:605-17. 10.1007\/s00592-018-1271-3","journal-title":"Acta Diabetol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000782","article-title":"Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"34","author":"Zhang X","year":"2016","unstructured":"Zhang X, Zhao Q. Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: a systematic review and meta-analysis. J Hypertens. 2016, 34:167-75. 10.1097\/HJH.0000000000000782","journal-title":"J Hypertens"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica BM","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, et al.. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013, 369:1317-26. 10.1056\/NEJMoa1307684","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock J","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE, et al.. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019, 321:69-79. 10.1001\/jama.2018.18269","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197321","article-title":"Efficacy and safety of saxagliptin in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"13","author":"Men P","year":"2018","unstructured":"Men P, Li XT, Tang HL, Zhai SD. Efficacy and safety of saxagliptin in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2018, 13:e0197321. 10.1371\/journal.pone.0197321","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0621","article-title":"Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial","volume":"40","author":"Mosenzon O","year":"2017","unstructured":"Mosenzon O, Leibowitz G, Bhatt DL, et al.. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care. 2017, 40:69-76. 10.2337\/dc16-0621","journal-title":"Diabetes Care"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1415","article-title":"Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS","volume":"39","author":"Cornel JH","year":"2016","unstructured":"Cornel JH, Bakris GL, Stevens SR, et al.. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS. Diabetes Care. 2016, 39:2304-10. 10.2337\/dc16-1415","journal-title":"Diabetes Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/396137-effectiveness-of-insulin-versus-oral-agents-in-patients-with-uncontrolled-type-2-diabetes-mellitus-a-retrospective-comparative-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T05:13:27Z","timestamp":1755321207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/396137-effectiveness-of-insulin-versus-oral-agents-in-patients-with-uncontrolled-type-2-diabetes-mellitus-a-retrospective-comparative-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.90196","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,15]]}}}